Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05434234 · ClinicalTrials.gov registry record · Phase 1

A Study of YL201 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
312
Enrollment target
20
Study locations

NCT05434234: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

NCT05434234 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 312 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05434234, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
312 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG YL201
  • DRUG YL201 and atezolizumab

Study Locations (20)

Texas

  • 014 - Houston
  • 015 - Irving
  • 013 - San Antonio
  • 016 - Tyler

California

  • 002 - Fair Oaks
  • 001 - La Jolla

Michigan

  • 006 - Ann Arbor
  • 007 - Detroit

Washington

  • 018 - Spokane
  • 019 - Tacoma

Colorado

  • 003 - Lone Tree

District of Columbia

  • 004 - Washington D.C.

Massachusetts

  • 005 - Boston

Missouri

  • 008 - St Louis

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2022-05-25
Est. Completion 2027-10-06
Phase Phase 1
MediLink Therapeutics (Suzhou) Co.

7 total trials

What NCT05434234 shows while recruiting

NCT05434234 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (63% higher).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which YL201 is the first listed.

NCT05434234 names 20 study sites across 14 states, led by Texas, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT05434234 about?

NCT05434234 is a clinical study titled "A Study of YL201 in Patients With Advanced Solid Tumors". This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor...

What is the current status of trial NCT05434234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2022-05-25. Estimated completion is 2027-10-06.

What conditions does trial NCT05434234 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05434234?

The interventions under investigation include: YL201 (DRUG), YL201 and atezolizumab (DRUG).

Who is sponsoring clinical trial NCT05434234?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05434234 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05434234's enrollment target sits among peer trials

312 34th of 189 higher than 156 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04984551 · 312 participants · Phase 2

    Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

  • NCT04999904 · 312 participants · NA

    A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability

  • NCT05220332 · 312 participants · NA

    Church-based Intervention to Improve Blood Pressure in African Americans

  • NCT05520593 · 312 participants · NA

    Preoperative Oral Hydration in the Ambulatory Arthroplasty Population

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05434234

Source: ClinicalTrials.gov NCT05434234, the US trial registry maintained by the National Library of Medicine. NCT05434234 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.